Ngā hua rapu - Amy Harker-Murray
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
-
2
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial mā Alain P. Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach-Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. Messino, Dennis F. Moore, Christopher D. Lao, Bryan A. Faller, Rangaswamy Govindarajan, Amy Harker-Murray, Luke Dreisbach, James Moon, Kenneth F. Grossmann, Antoni Ribas
I whakaputaina 2020Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Biology
Cancer
Chemotherapy
Internal medicine
Medicine
Oncology
Randomized controlled trial
Breast cancer
Cancer research
Cell biology
Clinical trial
Dabrafenib
Dosing
Kinase
MAPK/ERK pathway
MEK inhibitor
Melanoma
Metastatic melanoma
Neoadjuvant therapy
Paleontology
Progression-free survival
Randomization
Stage (stratigraphy)
Surgery
Trametinib
Urology
Vemurafenib